A study of two drugs, Lotrel (amlodipine/benazepril) and benazepril/HCTZ, for effectiveness in reducing heart disease and deaths from heart attacks.

Condition	Treatment or Intervention	Phase
Heart Disease	Drug: Lotrel (benazepril/amlodipine)  Drug: benazepril plus hydrochlorothiazide	Phase III

Further Study Details: 

Primary Outcomes: Cardiovascular morbidity; Cardiovascular mortality
Expected Total Enrollment:  12600

Ages Eligible for Study:  55 Years and above,  Genders Eligible for Study:  Both

Criteria

Inclusion Criteria:

• Adults with high risk hypertension.
• At least 55 years of age.
• Have elevated blood pressure and at least one other cardiovascular disease or diabetes or evidence of damage to the kidneys, brain, blood vessels or heart as defined in the protocol.

Exclusion Criteria:

• Allergy to any of the drugs administered in this trial.
• Selected laboratory tests.

More details provided by the study contact person.

Malcolm Bohm      862-778-6345    malcolm.bohm@pharma.novartis.com

New Jersey
      Malcolm Bohm, East Hanover,  New Jersey,  07936,  United States; Recruiting

Study ID Numbers:  CCIB002I2301
Record last reviewed:  December 2004
Last Updated:  December 21, 2004
Record first received:  November 30, 2004
ClinicalTrials.gov Identifier:  NCT00097864
Health Authority: United States: Food and Drug Administration
ClinicalTrials.gov processed this record on 2005-04-08